CA 19-9 is a glycoprotein most commonly measured as a tumour marker in patients with malignancies of the pancreas and hepatobiliary tree.
CA 19-9 is not suitable as a screening test for the primary diagnosis of tumours.
Cancer Antigen 19-9
If overnight - Frozen
CA 19-9 lacks sensitivity and specificity for any cancer and therefore it should not be used for screening or diagnostic purposes. However, CA 19-9 may be monitored in a patient with a known CA19-9 secreting tumour to assess for both response to treatment and recurrence or progression of known disease.
0 – 35 kUI/L
Paramagnetic particle, chemiluminescent immunoassay performed on Beckman Coulter DxI 800
$45.83 (Exclusive of GST)
"*" indicates required fields